Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2025

29 May–02 June 2025 | Chicago, IL & Online

The 2025 ASCO Annual Meeting took place in Chicago, IL, and online. This meeting attracted thousands of researchers and clinicians who shared the latest advances in the oncology field.

View all videos

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma

Shaji Kumar • 17 Jun 2025

The incidence of VTE following induction therapy in patients with newly diagnosed multiple myeloma

Muhamed Baljević • 14 Jun 2025

Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma

Shaji Kumar • 17 Jun 2025

CAR T-cell therapy for R/R secondary CNS lymphoma: real-world outcomes

Sairah Ahmed • 13 Jun 2025

CAR T-cell therapy for R/R secondary CNS lymphoma: real-world outcomes

Sairah Ahmed • 13 Jun 2025

Exploring the use of a novel deep learning-based MRI to better identify ICANS after CAR-T

Kathryn Tringale • 12 Jun 2025

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma

Shaji Kumar • 17 Jun 2025

The incidence of VTE following induction therapy in patients with newly diagnosed multiple myeloma

Muhamed Baljević • 14 Jun 2025

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma

Shaji Kumar • 17 Jun 2025

The incidence of VTE following induction therapy in patients with newly diagnosed multiple myeloma

Muhamed Baljević • 14 Jun 2025

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma

Shaji Kumar • 17 Jun 2025

Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma

Shaji Kumar • 17 Jun 2025